Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Kills bacteria by inhibiting cell wall synthesis. It is highly resistant to beta-lactamase produced by bacteria and is highly sensitive to Gram-positive, Gram-negative aerobic and anaerobic pathogens.

Sulfonylurea is an oral hypoglycemic diabetes treatment drug. It lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin, restores the peak of first-phase insulin secretion in response to glucose and increases first-phase insulin secretion. The insulin secretion response induced or stimulated by glucose after a meal is significantly increased. In addition, it partially inhibits platelet adhesion and aggregation, reduces platelet activity markers; produces fibrinolytic activity on the vascular endothelium (increases tPA activity), and reduces the process of microthrombosis formation.

Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. It mainly binds to the 50S subunit of the bacterial ribosome and inhibits RNA-dependent protein synthesis.

Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. It mainly binds to the 50S subunit of the bacterial ribosome and inhibits RNA-dependent protein synthesis.

Azithromycin is a 15-membered ring macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. It mainly binds to the 50S subunit of the bacterial ribosome and inhibits RNA-dependent protein synthesis.